[(Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) March 31, 2015 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY 4. CITIZENSHIP]
[(Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) March 31, 2015 (Date of Event Which Requires Filing of this Statement) [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * CUSIP No. 1. NAMES OF REPORTING PERSONS 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP 3. SEC USE ONLY 4. CITIZENSHIP]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 x o o (Check One): o o o For Period Ended: December 31, 2014 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]
[o x x o Large accelerated filer o Accelerated filer o Non-accelerated filer Do not check if a smaller reporting company x Smaller reporting company ¨ x Documents Incorporated by Reference: None. 2 FORM 10-K ANNUAL REPORT FISCAL YEAR ENDED DECEMBER 31, 2014 TABLE OF CONTENTS PAGE PART I] [Re: Service about being [Job Position] of China Pharma Holdings, Inc. [Date/Month/Year] Dear [ ], On behalf of the Board of Directors (the “Board”) of China Pharma Holdings, Inc. (the “Company”), I am pleased to welcome you to join the Board as [Job Position]. I look forward to working with you. Your starting date will be the date on which] [Loans Extension Confirmation Letter Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD44,213 respectively as of December 31, 2014. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 30, 2015 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2014 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 30, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 7 cphi10kex321123114.htm]
